As News.ro reports with reference to Reuters, the US Food and Drug Administration (FDA) re-approved Eli Lilly’s drug Jaypirca, which is used to treat a form of blood cancer.
The company said the health regulator has given new approval for the drug to treat chronic lymphocytic leukemia (CLL), a type of cancer in which the bone marrow produces too many of certain white blood cells.
Jaypirca first received accelerated FDA approval on January 27 for the treatment of mantle cell lymphoma (MCL), a rare type of blood cancer that starts in the white blood cells and spreads to other parts of the body.
MCL is a more aggressive form of cancer compared to CLL, according to the National Institutes of Health. The drug is indicated for the treatment of adults with CLL after at least two lines of therapy.
Source: Hot News
Ashley Bailey is a talented author and journalist known for her writing on trending topics. Currently working at 247 news reel, she brings readers fresh perspectives on current issues. With her well-researched and thought-provoking articles, she captures the zeitgeist and stays ahead of the latest trends. Ashley’s writing is a must-read for anyone interested in staying up-to-date with the latest developments.